Introduction
The efficacy of cisplatin-based concurrent chemo-radiotherapy (CCRT) over radiotherapy alone in cervical cancers has been well documented for more than 15 years. 1 CCRT was suggested for women who have locoregionally advanced cervical cancer that is confined to the pelvis and for women who require posthysterectomy radiotherapy for high-risk disease. 1 Cervical cancer typically occurs in the 5 th and 6 th decades of life;
< 20% of patients are older than 75 years 2 . Old aged patients' tolerance may be compromised because of their general performance status, comorbidities, and general concepts about short residual life. Therefore, administration of concurrent chemotherapy may increase the cost and complexity of treatment for elderly patients.
From our previous report and a report from Goodheart et al 3 , it is suggested that chemoradiation should be considered in elderly patients with invasive cervical cancer with decreased mortality compared with conventional radiotherapy alone 4 . Recently, standard radiotherapy treatment planning for cervical cancer has been shifting from conventional two-dimensional (2D) planning to 3D planning in order to achieve appropriate coverage of the target within sufficient dose and optimal sparing of organs at risk 5 .
Intensity-modulated radiotherapy (IMRT) is a promising form of 3D-conforming radiotherapy that produces a highly conformal dose closer to the target volumes and normal pelvic tissues (i.e., small bowel, bladder, rectum) are relatively spared. Treatment related toxicities might be reduced in patients with uterine cervical cancer by using IMRT alone 6, 7 . At the present time, there is not enough data to support routine use of IMRT for cervical cancer with CCRT, especially for the elderly.
Therefore, we reviewed our experience in elderly patients (aged 75 years) with good performance status treated in Mackay Memorial Hospital, Taipei, Taiwan from January 1, 2000 to June 6, 2013, and analyzed their survivals and compliance after CCRT with conventional 2D (2D-CCRT-group) versus IMRT (IM-CCRT-group), retrospectively.
Materials and Methods
From January 2000 to June 2013, there were 1250 cervical cancers treated with radiotherapy in Mackay Memorial Hospital. Sixty biopsy proven cervical cancers in patients aged 75 years with Eastern Cooperative Oncology Group performance status 0e1 after complete history, physical examination including cystoscopy and proctoscopy, and laboratory studies had received concurrent chemoradiotherapy (CCRT) with weekly intravenous cisplatin, retrospectively. The Institute Review Board of Mackay Memorial Hospital (MMH-I-S-157 and MMH-I-S-434) approved this study.
2D Radiotherapy was planned by using a Pinnacle Treatment Planning System (Philips Healthcare, Madison, WI, USA) or Eclipse IMX Planning System (Varian Associates, Inc., Palo Alto, CA, USA) and delivered by a linear accelerator (Clinac1800 or IX, Varian Associates, Inc., Palo Alto, CA, USA; Precise, Elekta Inc., Stockholm, Sweden) to target volumes including the primary lesion, the pelvic nodes and the common iliac lymph nodes. Paraaortic lymph nodes were included if metastases were detected in image examination. 2D Radiotherapy was delivered by an initial four-field box technique followed by a parallel-opposed technique at the time brachytherapy was begun. Margins of the anterior-posterior fields were the upper margin of L4e5 (superiorly), the lower margin of the obturator foramen or the lowest extension of the disease (inferiorly), and 1.5e2.0 cm beyond lateral margins of true bony pelvis. For the lateral fields, the anterior margin was the anterior edge of the pubic symphysis. The posterior margins at the S2eS3 interspaces were used.
A total of 45e50.4 Gy to the isocenter was prescribed in 25e28 fractions by 10e15 MV X-ray at 320 cGy/min. A supplemental dose of 5.4e9 Gy was given to the parametrium area when necessary. For patients with positive paraaortic lymph node metastasis, periaortic node irradiation was irradiated with 45 Gy of extended anteroposterior and posteroanterior fields in conjunction with whole pelvic radiation. High dose intracavitary brachytherapy was given following the initial 30e40 Gy of whole pelvis irradiation. Meanwhile, the RT plan was changed in anteroposterior/posteroanterior fields to achieve the intended prescription dose of 45e59.4 Gy. The designed prescription dose was delivered at 1.8e2.0 Gy daily fraction, five fractions per week.
IMRT was delivered by a 6e10 MV linear accelerator (Precise, or VMAT, Elekta Inc.) after CT (computed tomography) simulation in a supine position with customized immobilization devices to decrease variability in the daily setup. The planning target volumes and clinical target volumes were defined and contoured on the individual axial CT slices according to the guideline report from Small et al 8 for vaginal and nodal areas. A seven field equally spaced co-planner IMRT plan was generated using the dose-volume constraints described by RTOG 0413 8 . A patient whose disease was limited to IB2 received 50.4 Gy in 28 fractions over 5.5 weeks to the vaginal planning-target-volume (PTV) and nodal PTV. Patients with locally advanced diseases received 60 Gy in 30 fractions over 6 weeks to the gross tumor volume defined by the computed tomographic simulation after discussion with the radiologist, and 50.4 Gy in 30 fractions to the vaginal PTV and nodal PTV at the same time by using the simultaneous integrated boost technique. The prescription dose was the isodose which encompassed at least 97% vaginal PTV and nodal PTV. No more than 20% of any PTV received > 110% of its prescribed dose. No more than 1% of any PTV received < 93% of its prescribed dose. No more than 1% or 1 cc (whichever is smaller) of the tissue outside the PTVs received > 110% of the dose prescribed to the primary PTV. Normal tissues were strongly encouraged to remain within these limits: small bowel volume 30% to receive 40 Gy, rectum volume 35% to received 50 Gy, bladder volume 35% to receive 50 Gy, and femoral head volume 20% to receive 30 Gy. The isocenter was placed at the geometric center of the PTV. Orthogonal electronic portal images were taken weekly to verify the setup accuracy.
All patients received high dose rate iridium-192 brachytherapy after whole pelvic irradiation. Brachytherapy was delivered to point A at a total dose of 20e30 Gy in 4e6 fractions, twice a week, for a minimum cumulative external and intracavitary dose of 85 Gy and a maximal dose of 95 Gy. We used Henschke shielded afterloading applicators, set number 084400 (Radiation Products Design, Inc., Albertville, MN, USA) and iridium-192 for the isotope seed (Le Petten, North Holland, The Netherlands). Treatment was planned using the Plato Brachytherapy planning system version 14.2.4 (Nucletron International B.V., Veenendaal, The Netherlands).
All patients received at least 45 Gy in the whole pelvis, but none received more than 50.4 Gy. We attempted to complete the entire course of CCRT within 8 weeks, but chemotherapy was withheld if the neutrophil count was < 1500 cells/dL or the platelet count was < 10,000 cells/dL. In cases with Grade 3 hematologic or nonhematologic toxicity and decreased performance status, radiotherapy was halted until recovery of performance status.
Eligibility criteria for administration of chemotherapy included a serum creatinine level of < 1.5 mg/dL, absolute neutrophil count of > 1500 cells/dL, and a platelet count of > 100,000 cells/dL. Cisplatin (Fresenius KABI, Maharashtra, India) was administered beginning on the 1 st day of radiation at a dose of 40 mg/m 2 weekly, no more than 70 mg per dose, up to six doses. Cisplatin was withheld if the absolute neutrophil count was < 1000 cells/L, creatinine level > 2.0 mg/dL, or platelet count < 75,000 cells/dL. Patients were given transfusions with packed red blood cells to maintain a hemoglobin level > 10 g/L during CCRT. Chart review was used for toxicity analyses. Acute toxicities were graded weekly according to the National Cancer Institute Common Toxicity Criteria version 3.0. Chronic toxicities were graded weekly according the American Radiation Therapy Oncology Group criteria. Gastrointestinal, genitourinary, and hematological complications are among the most common undesirable side effects for patients treated with pelvic RT. A maximal grade of toxicities was recorded for statistical analysis.
After completion of treatment, patients received regular followup every 1e2 months in the 1 st year, then every 3 months subsequently. Overall survival (OS) and disease-free survival (DFS) were calculated from the date of treatment. Surviving patients were censored on the date of last follow-up. We confirmed the cause of death by correspondence, telephone, or medical record review. All data were analyzed with the SPSS program for Windows (version 13; IBM, Armonk, NY, USA). We used Pearson Chi-square test to find the significance of between-group differences in treatment groups and t tests for finding the significance of mean between groups. The Kaplan-Meier method compared by the logrank test was used for OS and DFS. A p value 0.05 was considered significant, and only two-sided results with assumed equal variance were used.
Results
The patient and tumor characteristics of these groups are summarized in Table 1 . Conventional 2D radiotherapy was received in 30 patients (2D-CCRT-group) and intensity-modulated radiotherapy was received in 30 patients (IM-CCRT-group). The median and mean follow-up durations of all patients were 41.7 months and 42.6 months (range, 1e101 months). The median age of patients in the IM-CCRT group was greater (80.5 years vs.77.8 years, p ¼ 0. 0044). There was no statistical difference in combined medical problems such as diabetes, hypertension, atherosclerosis, and chronic renal failure between the two groups. There was no statistical difference in histological type, The International Federation of Gynecology and Obstetrics (FIGO) stage, and performance status between the two groups. About 30% patients had diabetes, hypertension, or both. There were fewer patients with medical problems in the IM-CCRT-group, but not significantly. Only two cases with adenocarcinoma were noted in the IM-CCRT-group in this analysis. Around 60% patients had performance status one in both groups (p ¼ 0.793). The clinical stage distribution was identical in both groups (p ¼ 0.796) and about half of patients were staged as having locally advanced disease.
There was no statistical difference in receiving cycles of chemotherapy between the two groups (p ¼ 0.161). More cycles of chemotherapy were given in the 2D-CCRT-group than in the IM-CCRT-group.
Only two cases in IM-CCRT completed their treatment in 8 weeks, but 24 cases in 2D-CCRT completed their treatment in 56 days (p < 0.05). The mean treatment duration was significantly longer for IM-CCRT patients than for 2D-CCRT patients (66.1 days vs. 51.7 days, p < 0.05).
Up to December 2014, eight patients in the 2D-CCRT-group were lost, and none were lost in the IM-CCRT-group. The mean follow-up durations were the same in these groups (41.4 months vs. 43.7 months, p ¼ 0.729). One case in the IM-CCRT group had local recurrence with distant metastasis. The local recurrence and distant metastasis were significantly lower for the IM-CCRT-group than for the 2D-CCRT-group (local recurrence ¼ 1/30 vs. 7/30, p ¼ 0.023; distant recurrence ¼ 1/30 vs. 9/30, p ¼ 0.006). About 30% of cases died and the incidences were identical for these two groups (8/30 vs. 11/30, p ¼ 0.405). No cancer related death was noted in the IM-CCRT-group (0/30 vs. 6/30). Table 2 summarizes the frequency and severity of acute complication rates. Acute toxicities such as diarrhea, abdominal cramping, nausea, anemia, leukocytopenia, urinary tract infection, and dysuria were observed in this study. The chronic toxicities were mainly proctitis and cystitis. Acute Grade 2 and Grade 3 gastrointestinal toxicities tended to be more significant in the IM-CCRTgroup (2D-CCRT vs. IM-CCRT: Grade 2 ¼ 23% vs. 27%, Grade 3 ¼ 23% vs. 37%, p ¼ 0. 001). Acute genitourinary and hematologic toxicities were common with no differences in both groups (p ¼ 0.502, p ¼ 0.338).
The chronic toxicities in these two groups are summarized in Table 3 . Higher chronic gastrointestinal toxicity was noted in the IM-CCRT-group, but the p value was not significant (2D-CCRT vs. IM-CCRT: Grade 2 ¼ 17% vs. 23.3%, Grade 3 ¼ 0% vs. 13.3%, p ¼ 0.054). Chronic genitourinary toxicity was higher in patients receiving 2D-CCRT, but the p value was not significant (2D-CCRT vs. IM-CCRT: Grade 2 ¼ 13.3% vs. 6.7%, Grade 3 ¼ 3.3% vs. 0%, respectively, p ¼ 0.083).
The DFS and OS of the entire group are shown in Figure 1 . The 3-year OS of the 2D-CCRT-group and IM-CCRT-group were 70.2% and 78.8%, respectively. The 3-year DFS of the 2D-CCRT-group and IM-CCRT-group were 73.4% and 100%, respectively. The mean OS for patients in the 2D-CCRT-group and in the IM-CCRT-group were 69 months and 66 months, respectively. The mean DFS for patients in the 2D-CCRT-group and in the IM-CCRT-group were 79.86 months and 78.64 months, respectively. Patients who had IM-CCRT had better DFS then 2D-CCRT cases (p ¼ 0.014). The OS is identical in both groups (p ¼ 0.689).
Discussion
Optimal cancer treatment among the elderly is controversial. Currently, those patients with cervical and ovarian cancer are reported to receive less aggressive treatment when general performance, comorbidity, and treatment tolerance are taken into consideration 9, 10 . Our previous study revealed 2D radiotherapy with concurrent cisplatin chemotherapy was well tolerated in elderly patients with good performance. Although higher treatment related acute and chronic toxicities were noted, elderly patients with cervical cancer had a better overall outcome following chemoradiotherapy then radiation alone or incomplete radiotherapy 4 .
IMRT alone has been documented with lower treatment related toxicity and better tumor control than conventional radiotherapy alone 6, 7, 11 . There are many dosimetric studies that show a reduction of dose delivered to the pelvic organs-at-risk with IMRT compared with conventional RT in the treatment of cervical cancer 12e14 . Table 1 Characteristics between patients who received two-dimensional concurrent chemoradiotherapy (2D-CCRT) and intensity-modulated concurrent chemo-radiotherapy (IM-CCRT). Data are presented as n (%) or n (range). 2D-CCRT ¼ two-dimensional concurrent chemo-radiotherapy; Ad-CA ¼ adenocarcinoma; ECOG-PS ¼ Eastern Cooperative Oncology Group-Performance Status; FIGO ¼ The International Federation of Gynecology and Obstetrics; IM-CCRT ¼ intensity-modulated concurrent chemo-radiotherapy; SCC ¼ squamous cell carcinoma; SD ¼ standard deviation.
However, whole pelvis IMRT is still associated with considerable rectal and cystic toxicity 11 . In the present study, acute gastrointestinal toxicity and chronic gastrointestinal toxicity seemed higher in the IM-CCRT group. By reviewing IMRT planning, "hot spots" with high rectum and bladder volumes were sometimes unavoidable. This uncertain high dose would elevate the highest dose to the rectum and bladder. The difference in acute and chronic genitourinary toxicities between the groups was not significant (acute: 10% vs. 3%, p ¼ 0.52; chronic: 16.6% vs. 6.7%, p ¼ 0.083). For the bladder, the high dose volume ratio might not be high enough to produce a higher incidence of toxicity. However, for the rectum, this might be the cause of higher toxicity. This phenomenon might be exaggerated in the elderly because of more complex comorbidity and the combination of CCRT. Therefore, the guideline related to dose-volume constrains might need to be modified for the elderly. Further dose-volume study will be needed to address this question. with IMRT and conventional radiotherapy and the 3-year OS was 82.5% for patients treated with IMRT and concurrent chemotherapy and the complete response rate was 88% for IMRT cases 11 . In the present study, the 3-year actuarial OS of the IM-CCRT group was 78.8%. That means for the elderly patients with cervical cancer, aggressive treatment did not shorten their survival by comparing with the general population, even though higher gastrointestinal toxicity had been noted in our study.
A population-based study from Taiwan concluded that threedimensional conformal radiotherapy had better OS than 2D radiotherapy after adjustment for age, diabetes mellitus, hypertension, coronary heart disease, hyperlipidemia, side effects, urbanization level, geographic region, and enrollee category (5-year survival rate: 82.3% vs. 73%, p ¼ 0.007, the hazard ratio ¼1.82 with CI, 1.16e2.85) 15 . In our study, the 3-year progression-free survival of the IM-CCRT group was 100%. IM-CCRT did provide better 3-year DFS than 2D-CCRT, but the OS did not conclude in significant improvement by using IM-CCRT. Five deaths in the IM-CCRT group were not related to their cancers (1 with pneumonia, 2 with severe anemia, 2 with urosepsis). Causes of the other three deaths in the IM-CCRT group were unknown, but two patients developed other cancers during follow-up. Prolonged treatment times in cervical cancer treated with conventional radiotherapy were reported with poor pelvic control and cancer-specific survival in several retrospective studies 16, 17 . Song et al 17 reported that total treatment time over 56 days was not significantly affected by pelvic failure, distant failure, and disease specific mortality for cervical cancers treated with concurrent chemoradiotherapy. Reasons for treatment prolongation were multifactorial. The incidence of Grade 3þ acute toxicities and delayed time with brachytherapy were reported in analysis by Song et al 17 .
The incidence of Grade 3 acute gastrointestinal toxicities was significantly higher in the IM-CCRT group in our study and the fact that we started brachytherapy after the completion of IMRT might be the major reason for a prolonged treatment time. In our study, 93.3% of patients who received IM-CCRT had a prolonged treatment time over 56 days. The disease specific survival and OS were not affected by this factor, most likely because there were other modulating factors that affect outcome, such as more adequate tumor coverage with higher dose by IMRT than 2D, benefits of concurrent chemotherapy, and a physician's threshold for giving RT breaks for toxicities. The study published by Petereit et al 16 which mentioned a treatment range of 43e80 days yielded a significant difference in cell kill, particularly with shorter tumor doubling time; in addition, repopulation of proliferating tumor clonogens in cervical cancer may partially be negated by higher radiation doses. Therefore, in the IM-CCRT group, prolonged treatment time might Data are presented as n (%). 2D-CCRT ¼ two-dimensional concurrent chemo-radiotherapy; IM-CCRT ¼ intensity-modulated concurrent chemo-radiotherapy. Data are presented as n (%). 2D-CCRT ¼ two-dimensional concurrent chemo-radiotherapy; IM-CCRT ¼ intensity-modulated concurrent chemo-radiotherapy.
not be an important issue related to tumor control. Further randomized trials will be arranged to address these results. We acknowledge that this study has several limitations. First, the patient sample size is small in this retrospective study and the mean follow-up period is short. Reasons for the short follow-up were multifactorial. Old age, family care, and comorbidity may be related to the short follow-up. However, in this study the mean follow-ups in both groups were > 36 months, therefore we felt that the relatively short follow-up does not compromise the analysis for DFS. Second, the comorbid conditions influencing survival may be underestimated, such as diabetes may be a pretreatment prognostic factor in survival of cervical cancer 15 .
Our study suggested that IM-CCRT is feasible for elderly patients with cervical cancer but there should be caution in its application. IM-CCRT significantly increased acute gastrointestinal toxicities with encouraging preliminary clinical results compared with 2D-CCRT. Prolonged treatment time had no negative impact on tumor control in the IM-CCRT group. Large sample prospective clinical trials are needed to evaluate the benefits of IM-CCRT for cervical cancers.
